EGFR+ Lung Cancer

A 63-Year-Old Woman With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

In an interview with&nbsp;Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.<br /> &nbsp;

Lung Cancer

In response to&nbsp;frequent and substantial changes in the treatment of non&ndash;small cell lung cancer in the frontline set&shy;ting, the American Society of Clinical Oncology has partially updated its 2017 guide&shy;line for the treatment of patients with stage IV disease without driver mutations.

Patients harboring IDH1/2 muta&shy;tions may receive benefit by the use of PARP inhibitors, with investigators initi&shy;ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.

Julie R. Brahmer, MD, discusses the circumstances in which a physician can choose osimertinib over other EGFR tyrosine kinase inhibitors for patients with&nbsp;<em>EGFR</em>-mutant lung cancer.

Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the&nbsp;Journal for ImmunoTherapy of Cancer.

The addition of tremelimumab to frontline durvalumab and the standard of care, platinum-based chemotherapy, did not demonstrate a statistically significant improvement in overall survival in patients with extensive-stage small cell lung cancer, missing the co-primary end point of the phase III CASPIAN trial, according to high-level results from the final analysis of the trial.

To help assess the advances the United States has made in decreasing cancer-related deaths, a collective of public health bodies found that monitoring trends in cancer risk, screening test use, and mortality is informative. A report published in&nbsp;<em>Cancer</em>&nbsp;shows that progress has been made in recent years, but there is more work to be&nbsp;<a>done.</a>

From 2001 to 2017, the cancer death rates continued to decline in the United States, and these decreases were observed in all major racial and ethnic groups, as well as in males, females, adolescents, young adults, and children. However, the rates of cancer incidence for all cancers slightly increased in females from 2012 to 2016, according to the Annual Report to the Nation on the Status of Cancer, which was published in&nbsp;Cancer.^&nbsp;

Zofia Piotrowska, MD, MHS, discusses the rationale for conducting the FLAURA trial in patients with&nbsp;<em>EGFR</em>-mutant non&ndash;small cell lung cancer and how the use of osimertinib impacted the treatment landscape for this patient population.

A post hoc analysis of the ALTER 0303 trial has found that anlotinib, compared with placebo, extended the time patients with advanced non-small cell lung cancer had before brain metastases developed or existing brain lesions increased in size, reports a recent paper in The Oncologist.

In an interview with&nbsp;Targeted Oncology, Tony S. K. Mok, MD, BMSc, FRCPC, discussed the final progression-free survival data for frontline alectinib comparted with crizotinib as treatment of patients with advanced&nbsp;ALK-positive non&ndash;small cell lung cancer in the ALEX trial.

The FDA granted Breakthrough Therapy designation to JNJ-61186372 for the treatment of patients with metastatic non-small cell lung cancer with&nbsp;EGFR&nbsp;exon 20 insertion mutation whose disease has progressed on or after platinum-based chemotherapy.

The FDA has accepted a Biologics License Application for MYL-1402O, a proposed biosimilar to bevacizumab, according to a press release from co-developers Biocon and Mylan. The BLA is seeking approval for the biosimilar as a treatment for multiple types of cancer and the FDA has set an action date goal of December 27, 2020, for a decision on the BLA.

As the new coronavirus disease 2019 creates problems internationally, health-wise and economically, it is also becoming a cause for concern throughout the oncology community.